NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
05 10월 2023 - 9:30PM
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“Company” or “NurExone”), a biopharmaceutical company developing
biologically-guided exosome therapy (“ExoTherapy”) for patients
with traumatic spinal cord injuries, is excited to announce excited
to announce that Dr. Lior Shaltiel, CEO of NurExone Biologic, will
be presenting advances in exosome-based therapy for spinal cord
injury (SCI) and other traumatic central nervous system (CNS)
indications. Dr. Shaltiel’s presentation will focus on the
transformative potential of extracellular vesicles loaded with
PTEN-siRNA (ExoPTEN) and the key challenges in translating this
innovative therapy to the clinical stage, following the positive
response from the Company’s pre-IND meeting with the U.S. Food and
Drug Administration that was announced recently.
During the presentation, Dr. Shaltiel will
address critical aspects of NurExone’s ExoTherapy (exosome-based
therapy), including the loading efficiency of extracellular
vesicles (EVs) with siRNA and the large-scale production of EVs
utilizing a revolutionary 3D bioprocess concept. These advancements
represent a step forward in the field of recovery from spinal cord
injury and hold promise for patients globally.
The presentation will take place at the
Extracellular Vesicles Forum in Cambridge, UK, on October 10th and
11th at the session titled “Exosome Based Therapies and
Regenerative Medicine.” Dr. Shaltiel will be available for
one-on-one meetings during the conference.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated in animal studies at the Technion,
Israel Institute of Technology. NurExone is translating the
treatment to humans, and the company holds an exclusive worldwide
license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and
DirectorPhone: +972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect
management’s current beliefs and are based on information currently
available to management as at the date hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our ability to retain key personnel, our ability to
continue investing in research and development, our ability to
secure available funding and to continue as a going concern, the
general business and economic conditions of the industries and
countries in which we operate, our ability to execute on our
business strategy, that there will be certain amount of demand for
the Company’s potential product, inflation will remain stable, and
that the results of our studies reflect results that can be
extrapolated.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024